The MAP3K11 Knockout Raji Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population in which the MAP3K11 gene has been functionally disrupted, creating a loss-of-function model for studying mitogen-activated protein kinase (MAPK) signaling in a human B-lymphocyte background. This product provides a heterogeneous pool of Raji cells harboring targeted gene disruptions within the MAP3K11 locus, enabling pooled interrogation of JNK pathway biology without reliance on single-cell clonal isolates. The polyclonal knockout format preserves cellular diversity while abrogating MAP3K11-dependent signaling, making it suitable for experiments where population-level effects of MLK3 loss are prioritized over clonal homogeneity. Researchers can employ this system for genetic screening, signaling network deconvolution, and functional assays within a lymphoma-derived cellular context.
The Raji host cell line is an Epstein-Barr virus (EBV)-positive B-cell line originally isolated from a patient with Burkitt’s lymphoma, a highly aggressive B-cell malignancy. As mature B lymphocytes, Raji cells are proficient in antibody production, antigen presentation via major histocompatibility complex class II, and engagement of the adaptive immune response. Their transformed phenotype and lymphomagenic background make them a widely used model for B-cell biology, lymphoma pathogenesis, and therapeutic intervention studies. The EBV latency program drives constitutive activation of multiple growth and survival signals, including NF-??B and MAPK cascades, which intersect with endogenous stress and cytokine signaling networks. In this context, the MLK3-JNK axis is a critical node for integrating extracellular stimuli and modulating proliferative and apoptotic responses.
MAP3K11 encodes MLK3 (mixed-lineage kinase 3), a serine/threonine kinase that functions as a MAP kinase kinase kinase (MAPKKK) specifically activating the JNK branch of the MAPK pathway. MLK3 is activated by upstream regulators including TNFR1, TLR4, RAC1, CDC42, TRAF2, and inflammatory cytokines such as TNF-alpha and IL-1, and it also receives signals from TGF-beta receptors. Upon activation, MLK3 directly phosphorylates and activates the dual-specificity MAP2Ks MAP2K4 (MKK4) and MAP2K7 (MKK7), which in turn phosphorylate the JNK family (JNK1/2/3). Activated JNK translocates to the nucleus and phosphorylates transcription factors c-Jun and ATF2, leading to transcriptional regulation of genes involved in apoptosis (e.g., BCL2, BIM, p53), proliferation, and inflammation. MLK3 interacts with scaffold proteins like JIP1 and forms complexes with HSP90, AKT, and 14-3-3 proteins, which modulate its activity and stability. The representative pathway cascade MLK3?CMKK4/7?CJNK?Cc-Jun/ATF2 is a canonical stress-responsive signaling module.
In Raji B cells, the MAP3K11 knockout critically disables the JNK cascade downstream of diverse stress, cytokine, and growth factor receptors. Because Raji cells rely on integrated survival signals from EBV-driven oncogenic programs and autocrine/paracrine cytokine loops, loss of MLK3 disrupts the balance between pro-survival NF-??B and pro-apoptotic JNK outputs. This perturbation may sensitize cells to stress-induced apoptosis, alter expression of BCL2 family members, and impair transcriptional programs mediated by c-Jun and ATF2. Given the established role of JNK signaling in lymphomagenesis and chemoresistance, the knockout model is a valuable tool for dissecting how MLK3-dependent phosphorylation events contribute to B-cell lymphoma maintenance and for identifying synthetic lethal interactions or resistance mechanisms.
The MAP3K11 Knockout Raji Polyclonal Cells are designed for a range of advanced research applications, including mechanistic studies of JNK pathway regulation in B-cell lymphoma, apoptosis signaling assays, and functional genomics screens targeting the MAPK network. Typical experimental uses involve comparing wild-type and knockout cell populations via Western blotting for phospho-JNK and total JNK, RT-qPCR profiling of c-Jun and ATF2 target genes, flow cytometric apoptosis detection with Annexin V/PI staining, and cell viability assays under stress or drug treatment. The cells are also suitable for transcriptomic analyses by RNA-seq to identify global gene expression changes upon MLK3 loss and for drug sensitivity profiling with JNK inhibitors to explore therapeutic vulnerabilities. Researchers may employ this knockout model to investigate lymphomagenesis or to validate targets in inflammatory and neurodegenerative disease contexts. For additional details and customization, please contact Ascent Research.
